Concepedia

Author

Christopher Stone

GlaxoSmithKline (United Kingdom)ORCID

Also Known As

C Stone, C. Stone, C.H. Stone, Chris Stone, Christopher R. Stone, Christopher Stone

27

Publications

940

Citations

11

H-Index

13

Concepts

All Affiliations

GlaxoSmithKline (United Kingdom)Research Triangle Park FoundationSorbonne UniversitéAge UKWellcome Library
CS

About

Christopher Stone is an author at GlaxoSmithKline (United Kingdom) specializing in hiv, medicine, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

347

2

Immunology

1

1

158

3

Pharmacology

1

1

189

4

Drug Resistance

1

1

158

5

Neurovirology

1

1

189

Christopher Stone

×

11

Publications

919

Citations

11

H-Index

YearCitations

Pharmacokinetics and Antiretroviral Activity of Lamivudine Alone or When Coadministered with Zidovudine in Human Immunodeficiency Virus Type 1–Infected Pregnant Women and Their Offspring

Jagidesa Moodley, Dhayendre Moodley, Kubendran Pillay,

The Journal of Infectious Diseases

1998

189

Resistance Profile of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor Abacavir (1592U89) after Monotherapy and Combination Therapy

P. Richard Harrigan, Christopher Stone, Phillip Griffin,

The Journal of Infectious Diseases

2000

158

Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA

Nathan Clumeck, F. D. Goebel, Willy Rozenbaum,

AIDS

2001

145

HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy

Veronica Miller, Mounir Ait‐Khaled, Christopher Stone,

AIDS

2000

130

Antiviral Efficacy of Abacavir in Antiretroviral Therapy-Experienced Adults Harbouring HIV-1 with Specific Patterns of Resistance to Nucleoside Reverse Transcriptase Inhibitors

E. Randall Lanier, Mounir Ait‐Khaled, Janna Scott,

Antiviral Therapy

2004

71

The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial

Christine Katlama, Bonaventura Clotet, Andreas Plettenberg,

AIDS

2000

58

M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine

Mounir Ait‐Khaled, Christopher Stone, Gillian Amphlett,

AIDS

2002

53

Effect of concurrent zidovudine use on the resistance pathway selected by abacavir‐containing regimens

ER Lanier, Naomi Givens, Christopher Stone,

HIV Medicine

2004

40

Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutation Selection during In Vitro Exposure to Tenofovir Alone or Combined with Abacavir or Lamivudine

Christopher Stone, Mounir Ait‐Khaled, Charles Craig,

Antimicrobial Agents and Chemotherapy

2004

38

HIV-1 Reverse Transcriptase and Protease Resistance Mutations Selected during 16–72 Weeks of Therapy in Isolates from Antiretroviral Therapy-Experienced Patients Receiving Abacavir/Efavirenz/Amprenavir in the CNA2007 Study

Mounir Ait‐Khaled, Abdelrahim Rakik, Philip Griffin,

Antiviral Therapy

2003

25

Page 1